{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:11Z","timestamp":1786982771544,"version":"build-2736575974"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40272-022-00549-4","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T13:02:32Z","timestamp":1671368552000},"page":"151-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment Options for Juvenile Pityriasis Rubra Pilaris"],"prefix":"10.1007","volume":"25","author":[{"given":"Jana","family":"Guenther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Novack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2700-1041","authenticated-orcid":false,"given":"Scott","family":"Worswick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,18]]},"reference":[{"issue":"3","key":"549_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/DDG.13718","volume":"17","author":"C Kromer","year":"2019","unstructured":"Kromer C, Sabat R, Celis D, M\u00f6ssner R. Systemic therapies of pityriasis rubra pilaris: a systematic review. J Dtsch Dermatol Ges. 2019;17(3):243\u201359. https:\/\/doi.org\/10.1111\/DDG.13718.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"549_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/J.1525-1470.1986.TB00648.X","volume":"3","author":"C Gelmetti","year":"1986","unstructured":"Gelmetti C, Schiuma AA, Cerri D, Gianotti F. Pityriasis rubra pilaris in childhood: a long-term study of 29 cases. Pediatr Dermatol. 1986;3(6):446\u201351. https:\/\/doi.org\/10.1111\/J.1525-1470.1986.TB00648.X.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"549_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/ARCHDERM.1969.01610260051008","volume":"100","author":"CL Davidson","year":"1969","unstructured":"Davidson CL, Winkelmann RK, Kierland RR. Pityriasis rubra pilaris: a follow-up study of 57 patients. Arch Dermatol. 1969;100(2):175\u20138. https:\/\/doi.org\/10.1001\/ARCHDERM.1969.01610260051008.","journal-title":"Arch Dermatol"},{"issue":"5","key":"549_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/000155599750010517","volume":"79","author":"KB Sorensen","year":"1999","unstructured":"Sorensen KB, Thestrup-Pedersen K. Pityriasis rubra pilaris: a retrospective analysis of 43 patients. Acta Derm Venereol. 1999;79(5):405\u20136. https:\/\/doi.org\/10.1080\/000155599750010517.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"549_CR5","first-page":"221","volume":"110","author":"M Larregue","year":"1983","unstructured":"Larregue M, Champion R, Bressieux JM, Laidet B, Lorette G. Acute pityriasis rubra pilaris in the child: apropos of 4 cases. Ann Dermatol Venereol. 1983;110(3):221\u20138.","journal-title":"Ann Dermatol Venereol"},{"issue":"4","key":"549_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/JAMADERMATOL.2016.5384","volume":"153","author":"L Feldmeyer","year":"2017","unstructured":"Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol. 2017;153(4):304\u20138. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2016.5384.","journal-title":"JAMA Dermatol"},{"key":"549_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/BJD.21708","author":"BW Boudreaux","year":"2022","unstructured":"Boudreaux BW, Pincelli TP, Bhullar PK, et al. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. Br J Dermatol. 2022. https:\/\/doi.org\/10.1111\/BJD.21708.","journal-title":"Br J Dermatol"},{"key":"549_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.151911","author":"S Shao","year":"2021","unstructured":"Shao S, Chen J, Swindell WR, et al. Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris. JCI Insight. 2021. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.151911.","journal-title":"JCI Insight."},{"issue":"1","key":"549_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/J.JID.2021.06.009","volume":"142","author":"JL Strunck","year":"2022","unstructured":"Strunck JL, Cutler B, Rajpal B, et al. Pityriasis rubra pilaris response to IL-17A inhibition is associated with IL-17C and CCL20 protein levels. J Invest Dermatol. 2022;142(1):235-9.e1. https:\/\/doi.org\/10.1016\/J.JID.2021.06.009.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"549_CR10","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/J.JACI.2017.05.019","volume":"140","author":"M Akiyama","year":"2017","unstructured":"Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization diseases. J Allergy Clin Immunol. 2017;140(6):1545\u20137. https:\/\/doi.org\/10.1016\/J.JACI.2017.05.019.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"549_CR11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/J.1365-2133.1996.D01-1114.X","volume":"135","author":"L Misery","year":"1996","unstructured":"Misery L, Faure M, Claudy A. Pityriasis rubra pilaris and human immunodeficiency virus infection: type 6 pityriasis rubra pilaris? Br J Dermatol. 1996;135(6):1008\u20139. https:\/\/doi.org\/10.1046\/J.1365-2133.1996.D01-1114.X.","journal-title":"Br J Dermatol"},{"issue":"1","key":"549_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/J.1365-2230.1980.TB01676.X","volume":"5","author":"WAD Griffiths","year":"1980","unstructured":"Griffiths WAD. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980;5(1):105\u201312. https:\/\/doi.org\/10.1111\/J.1365-2230.1980.TB01676.X.","journal-title":"Clin Exp Dermatol"},{"issue":"8\u20139","key":"549_CR13","first-page":"931","volume":"128","author":"WAD Griffiths","year":"2001","unstructured":"Griffiths WAD, Ozluer S. Pityriasis rubra pilaris. Ann Dermatol Venereol. 2001;128(8\u20139):931\u20134.","journal-title":"Ann Dermatol Venereol"},{"issue":"6","key":"549_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/J.JAAD.2008.07.054","volume":"59","author":"CC Yang","year":"2008","unstructured":"Yang CC, Shih IH, Lin WL, et al. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan. J Am Acad Dermatol. 2008;59(6):943\u20138. https:\/\/doi.org\/10.1016\/J.JAAD.2008.07.054.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"549_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1067\/mjd.2002.124619","volume":"47","author":"DS Allison","year":"2002","unstructured":"Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol. 2002;47(3):386\u20139. https:\/\/doi.org\/10.1067\/mjd.2002.124619.","journal-title":"J Am Acad Dermatol"},{"key":"549_CR16","first-page":"786","volume-title":"Textbook of pediatric dermatology","author":"W Griffiths","year":"2006","unstructured":"Griffiths W. Pityriasis rubra pilaris. In: Harper J, Oranje A, Prose N, editors. Textbook of pediatric dermatology. Oxford: Blackwell, 2006. p. 786\u201392."},{"issue":"1","key":"549_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/J.AJHG.2012.05.010","volume":"91","author":"D Fuchs-Telem","year":"2012","unstructured":"Fuchs-Telem D, Sarig O, van Steensel MAM, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91(1):163\u201370. https:\/\/doi.org\/10.1016\/J.AJHG.2012.05.010.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"549_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/JAMADERMATOL.2016.3601","volume":"153","author":"T Takeichi","year":"2017","unstructured":"Takeichi T, Sugiura K, Nomura T, et al. Pityriasis rubra pilaris type V as an autoinflammatory disease by CARD14 mutations. JAMA Dermatol. 2017;153(1):66\u201370. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2016.3601.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"549_CR19","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/J.JID.2018.03.1525","volume":"138","author":"M Mellett","year":"2018","unstructured":"Mellett M, Meier B, Mohanan D, et al. CARD14 gain-of-function mutation alone is sufficient to drive IL-23\/IL-17-mediated psoriasiform skin inflammation in vivo. J Invest Dermatol. 2018;138(9):2010\u201323. https:\/\/doi.org\/10.1016\/J.JID.2018.03.1525.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"549_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/J.IMMUNI.2018.05.012","volume":"49","author":"M Wang","year":"2018","unstructured":"Wang M, Zhang S, Zheng G, et al. Gain-of-function mutation of Card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A. Immunity. 2018;49(1):66-79.e5. https:\/\/doi.org\/10.1016\/J.IMMUNI.2018.05.012.","journal-title":"Immunity"},{"issue":"2","key":"549_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/BJD.12952","volume":"171","author":"O Eytan","year":"2014","unstructured":"Eytan O, Sarig O, Sprecher E, van Steensel MAM. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol. 2014;171(2):420\u20132. https:\/\/doi.org\/10.1111\/BJD.12952.","journal-title":"Br J Dermatol"},{"issue":"3","key":"549_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/J.JAAD.2018.02.034","volume":"79","author":"BG Craiglow","year":"2018","unstructured":"Craiglow BG, Boyden LM, Hu R, et al. CARD14-associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol. 2018;79(3):487\u201394. https:\/\/doi.org\/10.1016\/J.JAAD.2018.02.034.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"549_CR23","first-page":"564","volume":"17","author":"N Raza","year":"2007","unstructured":"Raza N, Bari AU, Dar NR. Juvenile onset classical pityriasis rubra pilaris: every patient may not require systemic therapy. J Coll Physicians Surg Pak. 2007;17(9):564\u20135. PMID: 17903408.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"6","key":"549_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1046\/J.1468-3083.2000.00123-2.X","volume":"14","author":"E Selvaag","year":"2000","unstructured":"Selvaag E, H\u00e6dersdal M, Thomsen K. Pityriasis rubra pilaris: a retrospective study of 12 patients. J Eur Acad Dermatol Venereol. 2000;14(6):514\u20135. https:\/\/doi.org\/10.1046\/J.1468-3083.2000.00123-2.X.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"549_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2310\/7750.2012.12018","volume":"17","author":"JM Mercer","year":"2013","unstructured":"Mercer JM, Pushpanthan C, Anandakrishnan C, Landells IDR. Familial pityriasis rubra pilaris: case report and review. J Cutan Med Surg. 2013;17(4):226\u201332. https:\/\/doi.org\/10.2310\/7750.2012.12018.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"549_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/J.1365-2230.2000.00616.X","volume":"25","author":"CM Neess","year":"2000","unstructured":"Neess CM, Hinrichs R, Dissemond J, et al. Treatment of pruritus by capsaicin in a patient with pityriasis rubra pilaris receiving RE-PUVA therapy. Clin Exp Dermatol. 2000;25(3):209\u201311. https:\/\/doi.org\/10.1046\/J.1365-2230.2000.00616.X.","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"549_CR27","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/J.ADENGL.2021.05.005","volume":"112","author":"MS Zegpi-Trueba","year":"2021","unstructured":"Zegpi-Trueba MS, Navajas-Galimany L, Gonz\u00e1lez S, Ram\u00edrez-Cornejo C. Acute postinfection pityriasis rubra pilaris: excellent response to emollients and topical corticosteroids. Actas Dermosifiliogr. 2021;112(7):667\u20138. https:\/\/doi.org\/10.1016\/J.ADENGL.2021.05.005.","journal-title":"Actas Dermosifiliogr"},{"issue":"8","key":"549_CR28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S0001-7310(09)72284-7","volume":"100","author":"C Ferr\u00e1ndiz-Pulido","year":"2009","unstructured":"Ferr\u00e1ndiz-Pulido C, Bartralot R, Bassas P, et al. Acute postinfectious pityriasis rubra pilaris: a superantigen-mediated dermatosis. Actas Dermosifiliogr. 2009;100(8):706\u20139. https:\/\/doi.org\/10.1016\/S0001-7310(09)72284-7.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"549_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/J.1365-2133.1994.TB13121.X","volume":"130","author":"PCM van de Kerkhof","year":"1994","unstructured":"van de Kerkhof PCM, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol. 1994;130(5):675\u20138. https:\/\/doi.org\/10.1111\/J.1365-2133.1994.TB13121.X.","journal-title":"Br J Dermatol"},{"issue":"1","key":"549_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/J.1525-1470.2007.00603.X","volume":"25","author":"D Karimian-Teherani","year":"2008","unstructured":"Karimian-Teherani D, Parissa M, Tanew A. Response of juvenile circumscribed pityriasis rubra pilaris to topical tazarotene treatment. Pediatr Dermatol. 2008;25(1):125\u20136. https:\/\/doi.org\/10.1111\/J.1525-1470.2007.00603.X.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"549_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/J.1525-1470.1991.TB00311.X","volume":"8","author":"KD Arbegast","year":"1991","unstructured":"Arbegast KD, Braddock SW, Lamberty LF, Sawka AR. Treatment of infantile cystic acne with oral isotretinoin: a case report. Pediatr Dermatol. 1991;8(2):166\u20138. https:\/\/doi.org\/10.1111\/J.1525-1470.1991.TB00311.X.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"549_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S0022-3476(99)70255-6","volume":"134","author":"YM Mengesha","year":"1999","unstructured":"Mengesha YM, Hansen RC. Toddler-age nodulocystic acne. J Pediatr. 1999;134(5):644\u20138. https:\/\/doi.org\/10.1016\/S0022-3476(99)70255-6.","journal-title":"J Pediatr"},{"issue":"3","key":"549_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/J.1365-2133.2001.04397.X","volume":"145","author":"WJ Cunliffe","year":"2001","unstructured":"Cunliffe WJ, Baron SE, Coulson IH. A clinical and therapeutic study of 29 patients with infantile acne. Br J Dermatol. 2001;145(3):463\u20136. https:\/\/doi.org\/10.1046\/J.1365-2133.2001.04397.X.","journal-title":"Br J Dermatol"},{"issue":"4","key":"549_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/J.1525-1470.1988.TB00902.X","volume":"5","author":"D Rosinska","year":"1988","unstructured":"Rosinska D, Wolska H, Jablonska S, Konca I. Etretinate in severe psoriasis of children. Pediatr Dermatol. 1988;5(4):266\u201372. https:\/\/doi.org\/10.1111\/J.1525-1470.1988.TB00902.X.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"549_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/archderm.1987.01660260100023","volume":"123","author":"LS Shelnitz","year":"1987","unstructured":"Shelnitz LS, Esterly NB, Honig PJ. Etretinate therapy for generalized pustular psoriasis in children. Arch Dermatol. 1987;123(2):230\u20133. https:\/\/doi.org\/10.1001\/archderm.1987.01660260100023.","journal-title":"Arch Dermatol"},{"key":"549_CR36","doi-asserted-by":"publisher","unstructured":"Tamayo L, Ru\u00edz-Maldonado R.  Long-term follow-up of 30 children under oral retinoid Ro 10-9359. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper C, Polano MK, Schuppli R, editors.  Retinoids. Berlin, Heidelberg: Springer; 1981. https:\/\/doi.org\/10.1007\/978-3-642-68023-6_37.","DOI":"10.1007\/978-3-642-68023-6_37"},{"issue":"1","key":"549_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/JAMADERMATOL.2013.4773","volume":"150","author":"AB Eastham","year":"2014","unstructured":"Eastham AB, Femia AN, Qureshi A, Vleugels RA. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. JAMA Dermatol. 2014;150(1):92\u20134. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2013.4773.","journal-title":"JAMA Dermatol"},{"issue":"4 Pt 2 Suppl.","key":"549_CR38","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S0190-9622(82)70061-1","volume":"6","author":"LA Goldsmith","year":"1982","unstructured":"Goldsmith LA, Elise Weinrich A, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982;6(4 Pt 2 Suppl.):710\u20135. https:\/\/doi.org\/10.1016\/S0190-9622(82)70061-1.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"549_CR39","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.7205\/MILMED-D-15-00316","volume":"181","author":"SK Stacey","year":"2016","unstructured":"Stacey SK, Novek SJ, Maddox CL. Pityriasis rubra pilaris in a 3-year-old male. Mil Med. 2016;181(3):e298-301. https:\/\/doi.org\/10.7205\/MILMED-D-15-00316.","journal-title":"Mil Med"},{"issue":"4","key":"549_CR40","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/J.1365-2133.2007.08126.X","volume":"157","author":"JB Hong","year":"2007","unstructured":"Hong JB, Chiu HC, Wang SH, Tsai TF. Recurrence of classical juvenile pityriasis rubra pilaris in adulthood: report of a case. Br J Dermatol. 2007;157(4):842\u20134. https:\/\/doi.org\/10.1111\/J.1365-2133.2007.08126.X.","journal-title":"Br J Dermatol"},{"issue":"3","key":"549_CR41","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/ARCHDERM.1991.01680030061007","volume":"127","author":"NE McElwee","year":"1991","unstructured":"McElwee NE, Schumacher MC, Johnson SC, et al. An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch Dermatol. 1991;127(3):341\u20136. https:\/\/doi.org\/10.1001\/ARCHDERM.1991.01680030061007.","journal-title":"Arch Dermatol"},{"issue":"2","key":"549_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/120347540000400205","volume":"4","author":"PR Hull","year":"2000","unstructured":"Hull PR, Demkiw-Bartel C. Isotretinoin use in acne: prospective evaluation of adverse events. J Cutan Med Surg. 2000;4(2):66\u201370. https:\/\/doi.org\/10.1177\/120347540000400205.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"549_CR43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/J.1525-1470.1983.TB01096.X","volume":"1","author":"JJ DiGiovanna","year":"1983","unstructured":"DiGiovanna JJ, Peck GL. Oral synthetic retinoid treatment in children. Pediatr Dermatol. 1983;1(1):77\u201388. https:\/\/doi.org\/10.1111\/J.1525-1470.1983.TB01096.X.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"549_CR44","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0190-9622(88)70198-X","volume":"19","author":"H Gollnick","year":"1988","unstructured":"Gollnick H, Bauer R, Brindley C, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol. 1988;19(3):458\u201368. https:\/\/doi.org\/10.1016\/S0190-9622(88)70198-X.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"549_CR45","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/PDE.12940","volume":"33","author":"V di Lernia","year":"2016","unstructured":"di Lernia V, Bonamonte D, Lasagni C, et al. Effectiveness and safety of acitretin in children with plaque psoriasis: a multicenter retrospective analysis. Pediatr Dermatol. 2016;33(5):530\u20135. https:\/\/doi.org\/10.1111\/PDE.12940.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"549_CR46","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0190-9622(82)70148-3","volume":"7","author":"LM Milstone","year":"1982","unstructured":"Milstone LM, McGuire J, Ablow RC. Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol. 1982;7(5):663\u20136. https:\/\/doi.org\/10.1016\/S0190-9622(82)70148-3.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"549_CR47","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0190-9622(86)70300-9","volume":"15","author":"J Prendiville","year":"1986","unstructured":"Prendiville J, Bingham EA, Burrows D. Premature epiphyseal closure: a complication of etretinate therapy in children. J Am Acad Dermatol. 1986;15(6):1259\u201362. https:\/\/doi.org\/10.1016\/S0190-9622(86)70300-9.","journal-title":"J Am Acad Dermatol"},{"issue":"2 Pt 2","key":"549_CR48","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/0190-9622(95)90396-8","volume":"32","author":"RJ van Dooren-Greebe","year":"1995","unstructured":"van Dooren-Greebe RJ, van de Kerkhof PCM. Extensive extraspinal hyperostoses after long-term oral retinoid treatment in a patient with pityriasis rubra pilaris. J Am Acad Dermatol. 1995;32(2 Pt 2):322\u20135. https:\/\/doi.org\/10.1016\/0190-9622(95)90396-8.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"549_CR49","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/J.1365-2133.1987.TB05892.X","volume":"116","author":"MT Glover","year":"1987","unstructured":"Glover MT, Peters AM, Atherton DJ. Surveillance for skeletal toxicity of children treated with etretinate. Br J Dermatol. 1987;116(5):609\u201314. https:\/\/doi.org\/10.1111\/J.1365-2133.1987.TB05892.X.","journal-title":"Br J Dermatol"},{"key":"549_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-011-6349-1_4","author":"JG van der Schroeff","year":"1984","unstructured":"van der Schroeff JG, van der Rhee HJ.  The treatment of children with etretinate. In: Cunliffe WJ, Miller AJ, editors. Retinoid therapy.  Dordrecht: Springer; 1984. https:\/\/doi.org\/10.1007\/978-94-011-6349-1_4.","journal-title":"Retinoid Therapy."},{"issue":"4","key":"549_CR51","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/09546634.2017.1395798","volume":"29","author":"P Chen","year":"2018","unstructured":"Chen P, Li C, Xue R, et al. Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review. J Dermatolog Treat. 2018;29(4):353\u201363. https:\/\/doi.org\/10.1080\/09546634.2017.1395798.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"549_CR52","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/ARCHDERMATOL.2010.59","volume":"146","author":"P Vestergaard","year":"2010","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L. High-dose treatment with vitamin A analogues and risk of fractures. Arch Dermatol. 2010;146(5):478\u201382. https:\/\/doi.org\/10.1001\/ARCHDERMATOL.2010.59.","journal-title":"Arch Dermatol"},{"issue":"1","key":"549_CR53","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/PDE.14408","volume":"38","author":"AL Zaenglein","year":"2021","unstructured":"Zaenglein AL, Levy ML, Stefanko NS, et al. Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. Pediatr Dermatol. 2021;38(1):164\u201380. https:\/\/doi.org\/10.1111\/PDE.14408.","journal-title":"Pediatr Dermatol"},{"issue":"4 Pt 2 Suppl.","key":"549_CR54","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0190-9622(82)70053-2","volume":"6","author":"RK Brazzell","year":"1982","unstructured":"Brazzell RK, Colburn WA. Pharmacokinetics of the retinoids isotretinoin and etretinate: a comparative review. J Am Acad Dermatol. 1982;6(4 Pt 2 Suppl.):643\u201351. https:\/\/doi.org\/10.1016\/S0190-9622(82)70053-2.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"549_CR55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/IJD.14349","volume":"58","author":"L Chularojanamontri","year":"2019","unstructured":"Chularojanamontri L, Silpa-archa N, Wongpraparut C, Limphoka P. Long-term safety and drug survival of acitretin in psoriasis: a retrospective observational study. Int J Dermatol. 2019;58(5):593\u20139. https:\/\/doi.org\/10.1111\/IJD.14349.","journal-title":"Int J Dermatol"},{"key":"549_CR56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1744-859X-8-2","volume":"8","author":"VP Kontaxakis","year":"2009","unstructured":"Kontaxakis VP, Skourides D, Ferentinos P, Havaki-Kontaxaki BJ, Papadimitriou GN. Isotretinoin and psychopathology: a review. Ann Gen Psychiatry. 2009;8:2. https:\/\/doi.org\/10.1186\/1744-859X-8-2.","journal-title":"Ann Gen Psychiatry"},{"issue":"1","key":"549_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4088\/JCP.10R05993","volume":"73","author":"JD Bremner","year":"2012","unstructured":"Bremner JD, Shearer KD, McCaffery PJ. Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry. 2012;73(1):37\u201350. https:\/\/doi.org\/10.4088\/JCP.10R05993.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"549_CR58","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/J.SDER.2008.03.005","volume":"26","author":"AL Marqueling","year":"2007","unstructured":"Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg. 2007;26(4):210\u201320. https:\/\/doi.org\/10.1016\/J.SDER.2008.03.005.","journal-title":"Semin Cutan Med Surg"},{"issue":"6","key":"549_CR59","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/J.JAAD.2016.12.028","volume":"76","author":"YC Huang","year":"2017","unstructured":"Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;76(6):1068-76.e9. https:\/\/doi.org\/10.1016\/J.JAAD.2016.12.028.","journal-title":"J Am Acad Dermatol"},{"key":"549_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2018-021549","author":"C Li","year":"2019","unstructured":"Li C, Chen J, Wang W, Ai M, Zhang Q, Kuang L. Use of isotretinoin and risk of depression in patients with acne: a systematic review and meta-analysis. BMJ Open. 2019. https:\/\/doi.org\/10.1136\/BMJOPEN-2018-021549.","journal-title":"BMJ Open"},{"issue":"5","key":"549_CR61","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2340\/00015555-2885","volume":"98","author":"L Koch","year":"2018","unstructured":"Koch L, Sch\u00f6ffl C, Aberer W, Massone C. Methotrexate treatment for pityriasis rubra pilaris: a case series and literature review. Acta Derm Venereol. 2018;98(5):501\u20135. https:\/\/doi.org\/10.2340\/00015555-2885.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"549_CR62","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1111\/PDE.13326","volume":"35","author":"AH Boyd","year":"2018","unstructured":"Boyd AH, Polcari IC. Methotrexate treatment in a case of juvenile pityriasis rubra pilaris. Pediatr Dermatol. 2018;35(1):e62\u20133. https:\/\/doi.org\/10.1111\/PDE.13326.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"549_CR63","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/CED.13281","volume":"43","author":"A Alazemi","year":"2018","unstructured":"Alazemi A, Balakirski G, AlShehhi F, Lehmann S, Tenbrock K, Megahed M. Juvenile pityriasis rubra pilaris: successful treatment with methotrexate. Clin Exp Dermatol. 2018;43(1):110\u20132. https:\/\/doi.org\/10.1111\/CED.13281.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"549_CR64","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/1203475418775378","volume":"22","author":"ME MacGillivray","year":"2018","unstructured":"MacGillivray ME, Fiorillo L. Recurrent pityriasis rubra pilaris: a case report. J Cutan Med Surg. 2018;22(6):624\u20136. https:\/\/doi.org\/10.1177\/1203475418775378.","journal-title":"J Cutan Med Surg"},{"key":"549_CR65","unstructured":"Soriatane (acitretin) [package insert]. 2017. www.soriatane.com. Accessed 18 Aug 2022."},{"issue":"4","key":"549_CR66","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/J.JAAD.2010.05.007","volume":"64","author":"AD Searles","year":"2011","unstructured":"Searles AD, Lee AD, Feldman SR. Is concomitant use of methotrexate and oral retinoids dangerous? A review of the data regarding this combination. J Am Acad Dermatol. 2011;64(4):791\u20133. https:\/\/doi.org\/10.1016\/J.JAAD.2010.05.007.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"549_CR67","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000249755","volume":"167","author":"HI Beck","year":"1983","unstructured":"Beck HI, Foged EK. Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis. Dermatologica. 1983;167(2):94\u20136. https:\/\/doi.org\/10.1159\/000249755.","journal-title":"Dermatologica"},{"issue":"9","key":"549_CR68","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/ARCHDERM.1982.01650210040015","volume":"118","author":"EE Vanderveen","year":"1982","unstructured":"Vanderveen EE, Ellis CN, Campbell JP, Case PC, Voorhees JJ. Methotrexate and etretinate as concurrent therapies in severe psoriasis. Arch Dermatol. 1982;118(9):660\u20132. https:\/\/doi.org\/10.1001\/ARCHDERM.1982.01650210040015.","journal-title":"Arch Dermatol"},{"issue":"10","key":"549_CR69","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/ARCHDERM.1983.01650340003007","volume":"119","author":"JD Adams","year":"1983","unstructured":"Adams JD. Concurrent methotrexate and etretinate therapy for psoriasis. Arch Dermatol. 1983;119(10):793. https:\/\/doi.org\/10.1001\/ARCHDERM.1983.01650340003007.","journal-title":"Arch Dermatol"},{"issue":"2 Pt 2","key":"549_CR70","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0190-9622(84)80007-9","volume":"10","author":"MM Rosenbaum","year":"1984","unstructured":"Rosenbaum MM, Roenigk HH. Treatment of generalized pustular psoriasis with etretinate (Ro 10\u20139359) and methotrexate. J Am Acad Dermatol. 1984;10(2 Pt 2):357\u201361. https:\/\/doi.org\/10.1016\/S0190-9622(84)80007-9.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"549_CR71","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0190-9622(86)70009-1","volume":"14","author":"E Tuyp","year":"1986","unstructured":"Tuyp E, MacKie RM. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acad Dermatol. 1986;14(1):70\u20133. https:\/\/doi.org\/10.1016\/S0190-9622(86)70009-1.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"549_CR72","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/09546630701759579","volume":"19","author":"KE Lowenthal","year":"2008","unstructured":"Lowenthal KE, Horn PJ, Kalb RE. Concurrent use of methotrexate and acitretin revisited. J Dermatolog Treat. 2008;19(1):22\u20136. https:\/\/doi.org\/10.1080\/09546630701759579.","journal-title":"J Dermatolog Treat"},{"key":"549_CR73","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/J.PHRS.2017.04.014","volume":"121","author":"J An","year":"2017","unstructured":"An J, Zhang D, Wu J, et al. The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis. Pharmacol Res. 2017;121:158\u201368. https:\/\/doi.org\/10.1016\/J.PHRS.2017.04.014.","journal-title":"Pharmacol Res"},{"issue":"2","key":"549_CR74","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3949\/CCJM.50.2.201","volume":"50","author":"CW Hanke","year":"1983","unstructured":"Hanke CW, Steck WD. Childhood-onset pityriasis rubra pilaris treated with methotrexate administered intravenously. Cleve Clin Q. 1983;50(2):201\u20133. https:\/\/doi.org\/10.3949\/CCJM.50.2.201.","journal-title":"Cleve Clin Q"},{"issue":"1","key":"549_CR75","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/J.JAAD.2019.08.049","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161\u2013201. https:\/\/doi.org\/10.1016\/J.JAAD.2019.08.049.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"549_CR76","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/J.JAAD.2020.02.044","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445\u201386. https:\/\/doi.org\/10.1016\/J.JAAD.2020.02.044.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"549_CR77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ART.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun J, K\u00e4stner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73\u201381. https:\/\/doi.org\/10.1002\/ART.23144.","journal-title":"Arthritis Rheum"},{"key":"549_CR78","unstructured":"Methotrexate (Otrexup) [package insert]. 2019. www.fda.gov\/medwatch. Accessed 9 Oct 2022."},{"issue":"1","key":"549_CR79","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1046\/J.1365-2133.2003.05394.X","volume":"149","author":"T Wetzig","year":"2003","unstructured":"Wetzig T, Sticherling M. Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin. Br J Dermatol. 2003;149(1):202\u20133. https:\/\/doi.org\/10.1046\/J.1365-2133.2003.05394.X.","journal-title":"Br J Dermatol"},{"key":"549_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/S12969-019-0336-3","author":"S Signa","year":"2019","unstructured":"Signa S, Campione E, Rusmini M, et al. Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. Pediatr Rheumatol Online J. 2019. https:\/\/doi.org\/10.1186\/S12969-019-0336-3.","journal-title":"Pediatr Rheumatol Online J"},{"key":"549_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.14097","author":"JY Liang","year":"2020","unstructured":"Liang JY, Rui-Xian Y, Tian X, Zhang S-Q, Zhang X-B. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: a case report and literature review. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/DTH.14097.","journal-title":"Dermatol Ther"},{"key":"549_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.12559","author":"NJ Maloney","year":"2017","unstructured":"Maloney NJ, Hisaw LD, Worswick S. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: a retrospective investigation. Dermatol Ther. 2017. https:\/\/doi.org\/10.1111\/DTH.12559.","journal-title":"Dermatol Ther"},{"key":"549_CR83","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.12577","author":"V Lora","year":"2018","unstructured":"Lora V, de Felice C, Cota C, Graceffa D, Morrone A, Bonifati C. A case of juvenile pityriasis rubra pilaris type III successfully treated with etanercept. Dermatol Ther. 2018. https:\/\/doi.org\/10.1111\/DTH.12577.","journal-title":"Dermatol Ther"},{"issue":"2","key":"549_CR84","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/J.JDCR.2017.09.010","volume":"4","author":"L Bonomo","year":"2018","unstructured":"Bonomo L, Raja A, Tan K, Guttman-Yassky E. Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl. JAAD Case Rep. 2018;4(2):206\u201310. https:\/\/doi.org\/10.1016\/J.JDCR.2017.09.010.","journal-title":"JAAD Case Rep."},{"issue":"11","key":"549_CR85","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/1346-8138.13038","volume":"42","author":"BR Kim","year":"2015","unstructured":"Kim BR, Chae JB, Park JT, Byun SY, Youn SW. Clinical remission of pityriasis rubra pilaris with adalimumab in an adolescent patient. J Dermatol. 2015;42(11):1122\u20133. https:\/\/doi.org\/10.1111\/1346-8138.13038.","journal-title":"J Dermatol"},{"issue":"4","key":"549_CR86","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/PDE.14172","volume":"37","author":"MJ Chiramel","year":"2020","unstructured":"Chiramel MJ, Sathishkumar D, Edison ES, George R. Two cases of CARD14-associated papulosquamous eruption from India. Pediatr Dermatol. 2020;37(4):692\u20134. https:\/\/doi.org\/10.1111\/PDE.14172.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"549_CR87","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1684\/EJD.2020.3879","volume":"30","author":"C Kromer","year":"2020","unstructured":"Kromer C, Lippert U, Sch\u00f6n MP, M\u00f6ssner R. Treatment of pityriasis rubra pilaris: a case series of 28 patients. Eur J Dermatol. 2020;30(5):569\u201379. https:\/\/doi.org\/10.1684\/EJD.2020.3879.","journal-title":"Eur J Dermatol"},{"issue":"6","key":"549_CR88","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/JDV.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378. https:\/\/doi.org\/10.1111\/JDV.14888.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"549_CR89","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/J.JAAD.2018.03.036","volume":"79","author":"M Napolitano","year":"2018","unstructured":"Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: a review of the literature. J Am Acad Dermatol. 2018;79(2):353-9.e11. https:\/\/doi.org\/10.1016\/J.JAAD.2018.03.036.","journal-title":"J Am Acad Dermatol"},{"key":"549_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAAD.2008.06.016","author":"V Cox","year":"2008","unstructured":"Cox V, Lesesky EB, Garcia BD, O\u2019Grady TC. Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol. 2008. https:\/\/doi.org\/10.1016\/J.JAAD.2008.06.016.","journal-title":"J Am Acad Dermatol"},{"key":"549_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.13431","author":"Z Zhong","year":"2020","unstructured":"Zhong Z, Li J, Xue R, Liang Y, Chen Y. Refractory classic juvenile pityriasis rubra pilaris successfully treated with a combination of etanercept and methotrexate. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/DTH.13431.","journal-title":"Dermatol Ther"},{"issue":"4","key":"549_CR92","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1684\/EJD.2011.1325","volume":"21","author":"C Dessinioti","year":"2011","unstructured":"Dessinioti C, Vergou T, Moustou E, Katsambas A, Antoniou C. Long-term infliximab treatment for refractory type III juvenile pityriasis rubra pilaris. Eur J Dermatol. 2011;21(4):599\u2013600. https:\/\/doi.org\/10.1684\/EJD.2011.1325.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"549_CR93","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/J.1468-3083.2007.02282.X","volume":"22","author":"M Ruzzetti","year":"2008","unstructured":"Ruzzetti M, Saraceno R, Carboni I, Papoutsaki M, Chimenti S. Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab. J Eur Acad Dermatol Venereol. 2008;22(1):117\u20138. https:\/\/doi.org\/10.1111\/J.1468-3083.2007.02282.X.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"549_CR94","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/PDE.14779","volume":"38","author":"CP Frare","year":"2021","unstructured":"Frare CP, Blumstein AJ, Paller AS, et al. CARD14-associated papulosquamous eruption (CAPE) in pediatric patients: three additional cases and review of the literature. Pediatr Dermatol. 2021;38(5):1237\u201342. https:\/\/doi.org\/10.1111\/PDE.14779.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"549_CR95","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/BJD.15462","volume":"178","author":"SM Lwin","year":"2018","unstructured":"Lwin SM, Hsu CK, Liu L, Huang HY, Levell NJ, McGrath JA. Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14. Br J Dermatol. 2018;178(4):969\u201372. https:\/\/doi.org\/10.1111\/BJD.15462.","journal-title":"Br J Dermatol"},{"key":"549_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/BCR-2020-235287","author":"RM Nielsen","year":"2021","unstructured":"Nielsen RM, Gram SB, Bygum A. Identification of a pathogenic CARD14 mutation in a 70-year-old woman with pityriasis rubra pilaris: when genetic diagnosis influences choice of treatment strategy. BMJ Case Rep. 2021. https:\/\/doi.org\/10.1136\/BCR-2020-235287.","journal-title":"BMJ Case Rep"},{"key":"549_CR97","doi-asserted-by":"publisher","DOI":"10.5070\/D3263047986","author":"E Cook","year":"2020","unstructured":"Cook E, Tan KW, Kollipara S, Tarbox M, Akin R. A case of resistant pityriasis rubra pilaris responsive to combination acitretin and ustekinumab. Dermatol Online J. 2020. https:\/\/doi.org\/10.5070\/D3263047986.","journal-title":"Dermatol Online J"},{"key":"549_CR98","doi-asserted-by":"publisher","DOI":"10.1111\/PDE.14994","author":"M Katharina","year":"2022","unstructured":"Katharina M, Selhofer I, Md S, et al. Successful treatment of a child\u2019s pityriasis rubra pilaris (PRP) with ustekinumab and acitretin. Pediatr Dermatol. 2022. https:\/\/doi.org\/10.1111\/PDE.14994.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"549_CR99","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/IJD.15219","volume":"60","author":"V Amat-Samaranch","year":"2021","unstructured":"Amat-Samaranch V, Cubir\u00f3 X, Tubau C, Garcia-Melendo C, Puig L. Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab. Int J Dermatol. 2021;60(3):e112\u20134. https:\/\/doi.org\/10.1111\/IJD.15219.","journal-title":"Int J Dermatol"},{"issue":"7","key":"549_CR100","first-page":"706","volume":"14","author":"K Papp","year":"2015","unstructured":"Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706\u201314.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"549_CR101","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/J.JDCR.2016.09.006","volume":"2","author":"ML Gauci","year":"2016","unstructured":"Gauci ML, Jachiet M, Gottlieb J, et al. Successful treatment of type II pityriasis rubra pilaris with secukinumab. JAAD Case Rep. 2016;2(6):462\u20134. https:\/\/doi.org\/10.1016\/J.JDCR.2016.09.006.","journal-title":"JAAD Case Rep."},{"issue":"6","key":"549_CR102","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/BJD.18263","volume":"181","author":"D Cole","year":"2019","unstructured":"Cole D, Mohammad T, Lim H. Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab. Br J Dermatol. 2019;181(6):1331\u20132. https:\/\/doi.org\/10.1111\/BJD.18263.","journal-title":"Br J Dermatol"},{"issue":"11","key":"549_CR103","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/JAMADERMATOL.2016.3885","volume":"152","author":"D Schuster","year":"2016","unstructured":"Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful treatment of refractory pityriasis rubra pilaris with secukinumab. JAMA Dermatol. 2016;152(11):1278\u201380. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2016.3885.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"549_CR104","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/AJD.13614","volume":"62","author":"K Simpson","year":"2021","unstructured":"Simpson K, Dolianitis C. A case of treatment-resistant pityriasis rubra pilaris responsive to secukinumab. Australas J Dermatol. 2021;62(3):441\u20132. https:\/\/doi.org\/10.1111\/AJD.13614.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"549_CR105","doi-asserted-by":"publisher","first-page":"AB268","DOI":"10.1016\/j.jaad.2016.02.1035","volume":"74","author":"I Kevric","year":"2016","unstructured":"Kevric I, Sluzevich J. Response of persistent juvenile pityriasis rubra pilaris to secukinumab. J Am Acad Dermatol. 2016;74(5):AB268. https:\/\/doi.org\/10.1016\/j.jaad.2016.02.1035.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"549_CR106","first-page":"1063","volume":"3","author":"C Mariasy","year":"2016","unstructured":"Mariasy C, Sauder D. Remission of pityriasis rubra pilaris with IL-17A antagonist secukinumab. Austin J Dermatolog. 2016;3(5):1063.","journal-title":"Austin J Dermatolog."},{"issue":"1","key":"549_CR107","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/1346-8138.14709","volume":"46","author":"T Matsuda","year":"2019","unstructured":"Matsuda T, Yamazaki F, Ueda-Hayakawa I, Kambe N, Okamoto H. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12\/23 p40. J Dermatol. 2019;46(1):70\u20132. https:\/\/doi.org\/10.1111\/1346-8138.14709.","journal-title":"J Dermatol"},{"issue":"7","key":"549_CR108","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14740338.2022.2073349","volume":"21","author":"K Bardowska","year":"2022","unstructured":"Bardowska K, Krajewski PK, Tyczy\u0144ska K, Szepietowski JC. Safety evaluation of secukinumab in pediatric patients with plaque psoriasis. Expert Opin Drug Saf. 2022;21(7):867\u201382. https:\/\/doi.org\/10.1080\/14740338.2022.2073349.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"549_CR109","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/09546634.2020.1737638","volume":"33","author":"KK Wu","year":"2022","unstructured":"Wu KK, Dao H. Off-label dermatologic uses of IL-17 inhibitors. J Dermatolog Treat. 2022;33(1):41\u20137. https:\/\/doi.org\/10.1080\/09546634.2020.1737638.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"549_CR110","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/JAMADERMATOL.2020.0932","volume":"156","author":"D Haynes","year":"2020","unstructured":"Haynes D, Strunck JL, Topham CA, et al. Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial. JAMA Dermatol. 2020;156(6):668\u201375. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2020.0932.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"549_CR111","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/BJD.19147","volume":"183","author":"AS Paller","year":"2020","unstructured":"Paller AS, Seyger MMB, Alejandro Magari\u00f1os G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231\u201341. https:\/\/doi.org\/10.1111\/BJD.19147.","journal-title":"Br J Dermatol"},{"issue":"5","key":"549_CR112","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/JAMADERMATOL.2022.065.5","volume":"158","author":"AS Paller","year":"2022","unstructured":"Paller AS, Seyger MMB, Magarin\u00f5s GA, et al. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 2022;158(5):533\u201341. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2022.065.5.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"549_CR113","first-page":"337","volume":"6","author":"M G\u00f3mez","year":"2007","unstructured":"G\u00f3mez M, Ruelas MEH, Welsh O, Arcaute HD, Ocampo-Candiani J. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient. J Drugs Dermatol. 2007;6(3):337\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"549_CR114","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4103\/0378-6323.156196","volume":"81","author":"A Massa","year":"2015","unstructured":"Massa A, Vasconcelos P, de Almeida L, Filipe P. Pityriasis rubra pilaris mixed type III\/IV successfully treated with narrow band-ultraviolet B. Indian J Dermatol Venereol Leprol. 2015;81(4):435. https:\/\/doi.org\/10.4103\/0378-6323.156196.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"549_CR115","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5070\/D32P73G00T","volume":"11","author":"J Bragg","year":"2005","unstructured":"Bragg J, Witkiewicz A, Orlow SJ, Schaffer JV. Pityriasis rubra pilaris, type IV. Dermatol Online J. 2005;11(4):14.","journal-title":"Dermatol Online J"},{"issue":"2","key":"549_CR116","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/J.1365-2133.2000.03316.X","volume":"142","author":"B Kirby","year":"2000","unstructured":"Kirby B, Watson R. Pityriasis rubra pilaris treated with acitretin and narrow-band ultraviolet B (Re-TL-01). Br J Dermatol. 2000;142(2):376\u20137. https:\/\/doi.org\/10.1046\/J.1365-2133.2000.03316.X.","journal-title":"Br J Dermatol"},{"issue":"1","key":"549_CR117","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/J.1365-2230.2005.01931.X","volume":"31","author":"HE Iredale","year":"2006","unstructured":"Iredale HE, Meggitt SJ. Photosensitive pityriasis rubra pilaris. Clin Exp Dermatol. 2006;31(1):36\u20138. https:\/\/doi.org\/10.1111\/J.1365-2230.2005.01931.X.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"549_CR118","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1046\/J.1365-2133.2000.03388.X","volume":"142","author":"RA Herbst","year":"2000","unstructured":"Herbst RA, Vogelbruch M, Ehnis A, Kiehl P, Kapp A, Weiss J. Combined ultraviolet al radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br J Dermatol. 2000;142(3):574\u20135. https:\/\/doi.org\/10.1046\/J.1365-2133.2000.03388.X.","journal-title":"Br J Dermatol"},{"issue":"4","key":"549_CR119","first-page":"769","volume":"140","author":"P Kaskel","year":"1999","unstructured":"Kaskel P, Grundmann-Kollmann M, Schiller PI, et al. Bath-PUVA as a treatment for pityriasis rubra pilaris provoked by ultraviolet B. Br J Dermatol. 1999;140(4):769\u201370.","journal-title":"Br J Dermatol"},{"issue":"5","key":"549_CR120","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1684\/EJD.2019.3641","volume":"29","author":"C Engelmann","year":"2019","unstructured":"Engelmann C, Elsner P, Miguel D. Treatment of pityriasis rubra pilaris type I: a systematic review. Eur J Dermatol. 2019;29(5):524\u201337. https:\/\/doi.org\/10.1684\/EJD.2019.3641.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"549_CR121","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/J.1365-2133.2005.06356.X","volume":"152","author":"B Coras","year":"2005","unstructured":"Coras B, Vogt TH, Ulrich H, Landthaler M, Hohenleutner U. Fumaric acid esters therapy: a new treatment modality in pityriasis rubra pilaris? Br J Dermatol. 2005;152(2):388\u20139. https:\/\/doi.org\/10.1111\/J.1365-2133.2005.06356.X.","journal-title":"Br J Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00549-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T14:04:23Z","timestamp":1676469863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00549-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,18]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00549-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,18]]},"assertion":[{"value":"22 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding source was secured for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jana Guenther, Danielle Novack, Sonia Kamath, and Scott Worswick have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the preparation of the article and review of the current literature as well as the writing and editing of the first draft of the manuscript. All authors have read and approved of the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}